McDermott Will & Schulte, a global law firm

Byron S. Kalogerou is the founder of the Firm’s Life Science Industry Group and the senior partner in the Boston Corporate Practice. He helps clients execute on their growth strategies by guiding them through complex domestic and cross-border mergers and acquisitions and joint ventures and alliances. He also assists early stage life science companies in their capital raising efforts. Byron has extensive industry background in the life science, industrial and manufacturing sectors. He also acts as outside general counsel to a number of companies.

Byron spent 18 years in-house, where he served in various general counsel roles at Tyco International, including as general counsel of its fire and security and telecom businesses, and as general counsel of its international legal department, a function he created. Byron led many of Tyco’s largest acquisitions, including the $12 billion acquisition of AMP Inc. and the $850 million purchase of AT&T Submarine Systems, and handled hundreds of middle-market deals around the globe. Byron also handled Tyco’s initial foray into medical devices and led many of the deals that formed Covidien, now part of Medtronic.

Byron returned to law firm life 18 years ago with a desire to bring his keen sense of the “voice of the customer” to drive predictability, value and efficiency into the deal process. Byron is a legal project management pioneer and co-chair of the American Bar Association (ABA) Committee on Mergers and Acquisitions’ Task Force on Legal Project Management. He is co-editor of the ABA Guidebook “Using Legal Project Management in Merger & Acquisition and Joint Venture Transactions”, now in its third edition. Byron also created the first-of-its-kind web-based collaborative deal management portal, which the Firm adopted and embraced as part of Client Central. He is also one of the Firm’s primary contacts with the Association of Corporate Counsel.

Anthony Paronneau focuses his practice on a broad range of corporate and transactional matters, with a particular focus on the pharmaceutical, medical device, biotech, and healthcare sectors.

He has extensive experience representing life sciences companies, private equity funds, and venture capital firms in complex M&A and private equity transactions, including acquisitions, venture financings, joint ventures, and divestitures.

Anthony regularly advises emerging growth companies and VC investors on the structuring and negotiation of early- and late-stage funding rounds, and has acted on numerous high-profile cross-border and domestic transactions involving leading innovators in the healthtech and biotech spaces.

In addition, he counsels life sciences clients on strategic partnerships, collaborations, licensing agreements, and distribution arrangements, supporting their growth and commercialization strategies across all stages of development.

Emmanuelle Trombe is the co-head of the Firm’s Life Sciences industry practice. She represents pharmaceutical, medical device and bio-pharmaceutical companies globally in transactional matters in relation to M&A and divestitures, joint ventures and strategic partnerships, large-scale projects, outsourcing projects, product development, licensing agreements and regulatory matters. She also advises venture capital funds and bio-pharmaceutical companies in connection with a broad range of financing activities. As well as co-heading the Firm’s Life Sciences Group, Emmanuelle serves as an elected member of the Firm’s Management Committee.

Emmanuelle is distinguished in Chambers Europe and Legal 500 EMEA in life sciences transactions, where she is highly recommended for her experience in the pharmaceutical, healthcare, biotech and medical devices industries and described as very responsive, smart, flexible and business-minded. She has been distinguished as the Lawyer of the Year in Life Sciences for 2024.